ACSL6 Is Associated with the Number of Cigarettes Smoked and Its Expression Is Altered by Chronic Nicotine Exposure

Autor: Chen J, Dh, Brunzell, Jackson K, van der Vaart A, Jz, Ma, Tj, Payne, Sherva R, La, Farrer, Gejman P, Df, Levinson, Holmans P, Sh, Aggen, Damaj I, Po-Hsiu Kuo, Bt, Webb, Anton R, Hr, Kranzler, Gelernter J, Md, Li, Ks, Kendler, Chen X

Publikováno v: Europe PubMed Central
PLoS ONE, Vol 7, Iss 8 (2012)
PLoS ONE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63cfcaf0a743a1e891d24e91229f2f8b
http://europepmc.org/abstract/PMC/PMC3435233

CRISPR-Cas13b-mediated suppression of HBV replication and protein expression.

Autor: McCoullough LC; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Fareh M; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Hu W; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Sozzi V; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Makhlouf C; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Droungas Y; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Lee CL; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Takawy M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Fabb SA; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Payne TJ; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Pouton CW; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Netter HJ; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Lewin SR; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia., Purcell DF; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Holmes JA; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Littlejohn M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Revill PA; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. Electronic address: peter.revill@vidrl.org.au.

Publikováno v: Journal of hepatology [J Hepatol] 2024 Nov; Vol. 81 (5), pp. 794-805. Date of Electronic Publication: 2024 May 28.

Streamlined Clinical Management Pathways May Reduce Major Amputations in Patients with Chronic Limb Threatening Ischaemia: A Prospective Cohort Study with Historical Controls.

Autor: Houghton JSM; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK; National Institute for Health Research Leicester Biomedical Research Centre - The Glenfield Hospital, Leicester, UK. Electronic address: john.houghton@nhs.net., Meffen A; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Department of Population Health Sciences, University of Leicester, Leicester, UK., Gray LJ; National Institute for Health Research Leicester Biomedical Research Centre - The Glenfield Hospital, Leicester, UK; Department of Population Health Sciences, University of Leicester, Leicester, UK., Payne TJ; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; National Institute for Health Research Leicester Biomedical Research Centre - The Glenfield Hospital, Leicester, UK., Haunton VJ; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK., Davies RSM; Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK., Sayers RD; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK; National Institute for Health Research Leicester Biomedical Research Centre - The Glenfield Hospital, Leicester, UK.

Publikováno v: European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2024 Sep 10. Date of Electronic Publication: 2024 Sep 10.

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.

Autor: Nolan TM; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia. Electronic address: t.nolan@unimelb.edu.au., Deliyannis G; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Griffith M; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia., Braat S; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia., Allen LF; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Audsley J; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Chung AW; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Ciula M; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Gherardin NA; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Giles ML; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia., Gordon TP; Department of Immunology, Flinders University and SA Pathology, Flinders Medical Centre, Bedford Park, Adelaide, Australia., Grimley SL; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Horng L; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia., Jackson DC; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Juno JA; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Kedzierska K; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan., Kent SJ; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Lewin SR; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia., Littlejohn M; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia., McQuilten HA; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Mordant FL; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Nguyen THO; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Soo VP; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia., Price B; Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia., Purcell DFJ; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Ramanathan P; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Redmond SJ; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Rockman S; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; CSL Seqirus, Vaccine Innovation Unit, Parkville, Melbourne, Australia., Ruan Z; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Sasadeusz J; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia., Simpson JA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia., Subbarao K; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity, Australia., Fabb SA; Monash Institute of Pharmaceutical Sciences, Parkville, Australia., Payne TJ; Monash Institute of Pharmaceutical Sciences, Parkville, Australia., Takanashi A; Monash Institute of Pharmaceutical Sciences, Parkville, Australia., Tan CW; Duke NUS Medical School, Programme for Emerging Infectious Diseases, Singapore., Torresi J; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Wang JJ; Department of Immunology, Flinders University and SA Pathology, Flinders Medical Centre, Bedford Park, Adelaide, Australia., Wang LF; Duke NUS Medical School, Programme for Emerging Infectious Diseases, Singapore., Al-Wassiti H; Monash Institute of Pharmaceutical Sciences, Parkville, Australia., Wong CY; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia., Zaloumis S; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia., Pouton CW; Monash Institute of Pharmaceutical Sciences, Parkville, Australia., Godfrey DI; Department of Microbiology & Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Publikováno v: EBioMedicine [EBioMedicine] 2023 Dec; Vol. 98, pp. 104878. Date of Electronic Publication: 2023 Nov 27.

Association between electronic nicotine delivery systems (ENDS) device and E-liquid alterations and flavor use with clinical and EVALI-like symptoms.

Autor: Hart JL; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; Department of Communication, University of Louisville, Louisville, KY, USA., Payne TJ; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, MS, USA., Groom A; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; American Heart Association, Dallas, TX, USA., Tran H; NORC at the University of Chicago, Chicago, IL, USA., Walker KL; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; Department of Communication, University of Louisville, Louisville, KY, USA., Kesh A; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; American Heart Association, Dallas, TX, USA., Robertson RM; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; American Heart Association, Dallas, TX, USA., Vu TT; American Heart Association Tobacco Center for Regulatory Science (A-TRAC), Dallas, TX, USA.; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Publikováno v: Preventive medicine reports [Prev Med Rep] 2021 Oct 26; Vol. 24, pp. 101619. Date of Electronic Publication: 2021 Oct 26 (Print Publication: 2021).